Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500

Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research